title: Treatment of myelodysplastic syndromes with AML-type chemotherapy.
authors.affiliation: University of Texas, M.D. Anderson Cancer Center, Houston.
authors.forename: E
authors.initials: E
authors.lastname: Estey
authors.forename: S
authors.initials: S
authors.lastname: Pierce
authors.forename: H
authors.initials: H
authors.lastname: Kantarjian
authors.forename: S
authors.initials: S
authors.lastname: O'Brien
authors.forename: M
authors.initials: M
authors.lastname: Beran
authors.forename: M
authors.initials: M
authors.lastname: Andreeff
authors.forename: S
authors.initials: S
authors.lastname: Escudier
authors.forename: C
authors.initials: C
authors.lastname: Koller
authors.forename: S
authors.initials: S
authors.lastname: Kornblau
authors.forename: L
authors.initials: L
authors.lastname: Robertson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D003561:Cytarabine / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics; D011379:Prognosis; D012074:Remission Induction; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D014740:Vidarabine; C024352:fludarabine; D015255:Idarubicin